The sympathetic nervous system and the metabolic syndrome

被引:323
作者
Mancia, Giuseppe
Bousquet, Pascal
Elghozi, Jean Luc
Esler, Murray
Grassi, Guido
Julius, Stevo
Reid, John
Van Zwieten, Peter A.
机构
[1] Univ Milano Bicocca, Osped San Geraldo Tintori, I-20052 Monza, Milan, Italy
[2] Univ Strasbourg, Fac Med, Strasbourg, France
[3] Hop Necker Enfants Malad, UF Pharmacol Clin, Paris, France
[4] Baker Med Res Inst, Melbourne, Vic, Australia
[5] Univ Michigan Hlth Syst, Dept Internal Med, Ann Arbor, MI USA
[6] Univ Glasgow, Dept Med & Therapeut, Gardiner Inst, Glasgow, Lanark, Scotland
[7] Univ Amsterdam, Acad Med Ctr, Dept Pharmacotherapy, NL-1105 AZ Amsterdam, Netherlands
[8] Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands
[9] Univ Amsterdam, Acad Med Ctr, Dept Cardiopulm Surg, NL-1105 AZ Amsterdam, Netherlands
关键词
central sympatholytic drugs; hypertension; insulin; metabolic syndrome; obesity; sleep apnoea; sympathetic nervous system;
D O I
10.1097/HJH.0b013e328048d004
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Studies performed in the past two decades have unequivocally shown that several of the components of the metabolic syndrome are associated with indirect and direct markers of adrenergic overdrive. This is the case for hypertension and obesity, in which resting tachycardia, elevated plasma norepinephrine values, increased sympathetic nerve traffic, as well as augmented levels of total and regional norepinephrine spillover have been reported. This is also the case for insulin resistance, i.e. a metabolic condition frequently complicating the various components of the pathological condition identified as the 'metabolic syndrome'. After briefly describing the epidemiological and the cardiovascular risk profile of the disease, this paper will examine the behaviour of the sympathetic nervous system in the metabolic syndrome as well as the mechanisms potentially responsible for this neurogenic abnormality. This will be followed by an analysis of the role played by neuroadrenergic factors in disease progression as well as in the pathogenesis of its complications. Finally, the therapeutic implications of these findings will be highlighted.
引用
收藏
页码:909 / 920
页数:12
相关论文
共 131 条
[1]   The metabolic syndrome - a new worldwide definition [J].
Alberti, KGMM ;
Zimmet, P ;
Shaw, J .
LANCET, 2005, 366 (9491) :1059-1062
[2]   ELEVATED SYMPATHETIC-NERVE ACTIVITY IN BORDERLINE HYPERTENSIVE HUMANS - EVIDENCE FROM DIRECT INTRANEURAL RECORDINGS [J].
ANDERSON, EA ;
SINKEY, CA ;
LAWTON, WJ ;
MARK, AL .
HYPERTENSION, 1989, 14 (02) :177-183
[3]   INSULIN INCREASES SYMPATHETIC ACTIVITY BUT NOT BLOOD-PRESSURE IN BORDERLINE HYPERTENSIVE HUMANS [J].
ANDERSON, EA ;
BALON, TW ;
HOFFMAN, RP ;
SINKEY, CA ;
MARK, AL .
HYPERTENSION, 1992, 19 (06) :621-627
[4]   Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipid and glucose levels in hypertensive women with metabolic syndrome [J].
Anichkov, DA ;
Shostak, NA ;
Schastnaya, OV .
CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (01) :113-119
[5]   Free fatty acids and pathogenesis of type 2 diabetes mellitus [J].
Bergman, RN ;
Ader, M .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2000, 11 (09) :351-356
[6]  
Borch-Johnsen K, 1999, LANCET, V354, P617
[7]   The cardiac beta-adrenoceptor-mediated signaling pathway and its alterations in hypertensive heart disease [J].
Castellano, M ;
Bohm, M .
HYPERTENSION, 1997, 29 (03) :715-722
[8]   The metabolic syndrome and chronic kidney disease in US adults [J].
Chen, J ;
Muntner, P ;
Hamm, LL ;
Jones, DW ;
Batuman, V ;
Fonseca, V ;
Whelton, PK ;
He, J .
ANNALS OF INTERNAL MEDICINE, 2004, 140 (03) :167-174
[9]   Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (The Strong Heart study) [J].
Chinali, M ;
Devereux, RB ;
Howard, BV ;
Roman, MJ ;
Bella, JN ;
Liu, JE ;
Resnick, HE ;
Lee, ET ;
Best, LG ;
de Simone, G .
AMERICAN JOURNAL OF CARDIOLOGY, 2004, 93 (01) :40-44
[10]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497